Prothena Corp Public (PRTA) Non-Current Deffered Revenue (2012 - 2025)
Prothena Corp Public's (PRTA) quarterly Non-Current Deffered Revenue came in at $1.6 million in Q1 2025, down 97.59% year-on-year from $67.4 million in Q1 2024, and down 52.96% quarter-over-quarter from $3.4 million in Q4 2024.
Prothena Corp Public (PRTA) Non-Current Deffered Revenue (2012 - 2025) Analysis & Trends
Prothena Corp Public's Non-Current Deffered Revenue history runs 14 years deep, the most recent figure standing at $1.6 million for Q1 2025.
- On a quarterly basis, Non-Current Deffered Revenue fell 97.59% year-over-year to $1.6 million in Q1 2025; TTM through Mar 2025 was $1.6 million, a 97.59% decrease from a year earlier, with the FY2024 full-year figure at $3.4 million, down 94.88% from the prior year.
- Non-Current Deffered Revenue fell to $1.6 million in Q1 2025 per PRTA's latest filing, from $3.4 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $110.2 million in Q1 2021 and bottomed at $1.6 million in Q1 2025.
- The 5-year median for Non-Current Deffered Revenue is $85.3 million (2021), against an average of $68.1 million.
- Across the five-year window, Non-Current Deffered Revenue grew 15.31% in 2022 and plunged 97.59% in 2025, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $102.9 million in 2021, then slipped by 17.14% to $85.3 million in 2022, then retreated by 20.97% to $67.4 million in 2023, then slumped by 94.88% to $3.4 million in 2024, then slumped by 52.96% to $1.6 million in 2025.
- Per Business Quant, the three latest PRTA Non-Current Deffered Revenue figures stand at $1.6 million (Q1 2025), $3.4 million (Q4 2024), and $5.6 million (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 5.60 Mn |
| Jun 30, 2024 | 7.37 Mn |
| Mar 31, 2024 | 67.41 Mn |
| Dec 31, 2023 | 67.41 Mn |
| Sep 30, 2023 | 67.41 Mn |
| Jun 30, 2023 | 67.41 Mn |
| Mar 31, 2023 | 85.29 Mn |
| Dec 31, 2022 | 85.29 Mn |
| Sep 30, 2022 | 96.99 Mn |
| Jun 30, 2022 | 98.35 Mn |
| Mar 31, 2022 | 100.64 Mn |
| Dec 31, 2021 | 102.93 Mn |
| Sep 30, 2021 | 104.56 Mn |
| Jun 30, 2021 | 85.29 Mn |
| Mar 31, 2021 | 110.24 Mn |
| Dec 31, 2020 | 110.24 Mn |
| Sep 30, 2020 | 110.24 Mn |
| Jun 30, 2020 | 110.24 Mn |